BioCryst Pharmaceuticals, Inc. (BCRX) P/E Ratio History
Deep ValueTrading at -5.7x · 0th percentile of 5-year range · Significant discount to historical valuation · Data 2025–2025
Loading P/E history...
P/E Ratio Analysis
As of November 9, 2026, BioCryst Pharmaceuticals, Inc. (BCRX) trades at a price-to-earnings ratio of -5.7x, with a stock price of $7.69 and trailing twelve-month earnings per share of $-1.34.
The current P/E is 188% below its 5-year average of 6.5x. Over the past five years, BCRX's P/E has ranged from a low of 6.5x to a high of 6.5x, placing the current valuation at the 0th percentile of its historical range.
Compared to the Healthcare sector median P/E of 24.6x, BCRX trades at a 123% discount to its sector peers. The sector includes 242 companies with P/E ratios ranging from 0.0x to 196.0x.
Relative to the broader market, BCRX trades at a notable discount to the S&P 500 median P/E of 21.8x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our BCRX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
BCRX Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
BCRX P/E vs Peers
Rare Disease Commercial Leaders peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $4B | 10.3Lowest | - | +68%Best | |
| $60B | 47.2 | - | +54% | |
| $12B | 26.2 | 1.14 | -25% | |
| $45B | 32.6 | 0.80Best | +5% | |
| $16B | 408.0 | - | -1555% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
BCRX Historical P/E Data (2025–2025)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Dec 31 2025 | $7.80 | $1.20 | 6.5x | +0% |
Average P/E for displayed period: 6.5x
BCRX Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
1+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
BCRX — Frequently Asked Questions
Quick answers to the most common questions about buying BCRX stock.
What is BCRX's P/E ratio?
BioCryst Pharmaceuticals, Inc. (BCRX) trailing twelve-month P/E ratio is -5.7x, based on TTM diluted EPS of $-1.34. The 5-year average P/E is 6.5x and the historical range spans 6.5x to 6.5x.
Is BCRX stock overvalued or undervalued?
BCRX trades at -5.7x P/E, below its 5-year average of 6.5x. At the 0th percentile of its historical range (6.5x–6.5x), the stock is priced at a discount to its own history.
Is BCRX stock expensive?
No, BCRX is not expensive on a historical basis. The current P/E of -5.7x is below the 5-year average of 6.5x and sits at the 0th percentile of its valuation range.
What is BCRX's historical P/E range?
Over the past 5 years, BCRX's P/E ratio has ranged from 6.5x to 6.5x, with a median of 6.5x and an average of 6.5x. The current P/E of -5.7x places the stock at the 0th percentile of this range. Full historical data spans 2025–2025.
How does BCRX's P/E compare to the S&P 500?
BCRX trades at -5.7x P/E versus the S&P 500 median of 21.8x. The 126% discount to the market suggests lower growth expectations or perceived higher risk.
How does BCRX's valuation compare to Healthcare peers?
BioCryst Pharmaceuticals, Inc. P/E of -5.7x compares to the Healthcare sector median of 24.6x. The discount suggests lower growth expectations, weaker margins, or higher perceived risk relative to peers. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is BCRX's PEG ratio?
BCRX PEG ratio is N/A, based on a P/E of -5.7x and EPS growth of 381.4%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is BCRX's earnings yield?
BCRX earnings yield is N/A, the inverse of its -5.7x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.